FDA starts review of potentially first NASH treatment
The first drug to treat pre-cirrhotic liver fibrosis due to NASH in the US could be approved this summer, after Intercept Pharmaceuticals submits obeticholic acid (OCA) for FDA review.
by christian bundgaard, translated by daniel pedersen
US-based biotech firm Intercept Pharmaceuticals is on track to becoming the first company to have a non-alcoholic steatohepatitis (NASH) treatment market authorized in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Northsea: NASH candidate data coming soon
For subscribers
Altimmune meets NASH goal in phase I
For subscribers
